FDA 483 - Lin Shen - November 17, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Shen, Lin, MD, a clinical investigator in Beijing, China, revealed significant deviations from the investigational plan for a Phase 3 study on metastatic gastric or gastroesophageal junction adenocarcinoma. The firm failed to adhere to the study protocol by enrolling subjects who met exclusion criteria and by not discontinuing a subject experiencing a severe adverse event. These findings indicate a lack of adherence to the study's established procedures.
ID · a99e9c42-053c-4486-a43a-1bb7b082e4d8